This presentation will provide the prescriber with the latest evidence-based strategies for anti-obesity medications. This will include an overview of FDA-approved medications and those in the pipeline. A review of obesogenic medications will be included with possible alternatives. With nearly 70% of Americans with pre-obesity or obesity, it is imperative that NPs understand the medication options for treating the chronic, progressive, relapsing neuroendocrine disease of obesity.

 

An update on potassium-competitive acid blocker (PCAB) and proton pump inhibitor (PPI) prescribing for the Advanced Practice Provider. Proton pump inhibitors (PPI) are one of the most common prescribed medications, it is estimated that that over 100 million prescriptions for PPIs are filled annually. In 2023 PCABs, a new class of therapy had been approved. Up-to-date knowledge regarding acid blocker therapy remains essential in clinical practice. As an advanced practice provider, it is imperative to understand this new class of therapy and current data about PCAB/PPI safety so as to appropriately educate our patients.

 

Obesity is a chronic, progressive, relapsing disease that is treatable. Pharmacotherapy is one of the four pillars of comprehensive obesity treatment and may increase adherence to the other three pillars of nutritional therapy, physical activity, and behavior modification. Despite their safety and efficacy, only 1.3% of those eligible receive a prescription for FDA-approved anti-obesity medications. This presentation will help you unlearn any outdated or biased beliefs about these medications and learn the latest science on how you can use them safely and effectively. Real-life clinical scenarios will help you learn how to select, initiate, titrate, and monitor these medications. Tips and strategies for personalized medication selection based on complications, co-existing conditions, symptoms, patient preference, cost, and insurance coverage will be provided.

 

This presentation will provide a review and update on empiric "bugs and drugs" commonly encountered in emergency care. A brief review of the classes of medications and their common side effects and interactions will be reviewed. Using a body system approach, the current recommendations for appropriate empiric agents will be reviewed including HEENT, CAP, SSSTI, STI, and UTI. Systemic problems such as sepsis and viral infections including influenza, CoV-19, and zoster will also be discussed. The importance of antimicrobial stewardship will be addressed throughout.

 

Each year, the American Diabetes Association publishes an update of their recommendations regarding the use of diabetes medications. The recommendations are based on the latest research. There have been many recent changes in the past 1-2 years. Most of the over 37 million patients with diabetes in the United States do not see an endocrinologist, and many see a Nurse Practitioner. There are now more than 100 diabetes medications and 13 diabetes drug classes on the market, making it difficult for the Nurse Practitioner to know where to start and how to adjust. This lecture will discuss how the different diabetes medication classes work and the new recommendations for initiating, titrating, and combining diabetes medication classes with a patient-centered approach to achieve glycemic targets.

 

Attendees will learn and synthesize current evidence-based practices and guidelines in caring for men. They will learn how to utilize current evidence-based practices in a language that resonates well with the men they care for in their home communities. We will cover strategies that will assist the NP in recruiting, retaining, and engaging men in primary preventive Health Care.

 

Interleukin and Janus Kina's inhibitors provide new treatment modalities for dermatoses and cutaneous diseases. These medications are highly efficacious, but their management can be complex. This presentation will enhance the NPs knowledge of the key components in working with patients taking these drugs.

 

Oncologic emergencies can present in a wide variety of acute care settings. These emergencies can be caused from the cancer itself, a paraneoplastic syndrome, or from treatment of cancer. This session explores the etiologies and treatment of metabolic and structural oncological emergent medical conditions. Learners will apply this information to complex oncology patients with comorbid conditions across the spectrum of acute care. Discussions include a wide variety of topics that encompass multiple body systems including neurological, metabolic, cardiovascular, hematological, pulmonary and gastrointestinal. This presentation outlines evidence-based practice recommendations to maximize the quality of care. Additional information will be provided about evolving complications associated with immune checkpoint inhibitors and CAR-T cell therapy, both common immunotherapies for cancer care.

 

Pain management is a frequent aspect of managing patients in emergency care settings. This can sometimes be complicated by the patient's medical history, including allergies or the presence of substance abuse, as well as legal requirements. This presentation will provide a review of pain management, including multimodal options. Current practice guidelines and options related to the management of opioid use disorder will be introduced. By the end of the presentation, emergency nurse practitioners will have an increased awareness of pain management options.

 

This presentation examines the most current epidemiologic data on HIV infection in the United States, including an overview of persons at highest risk, the most recent data on incidence and prevalence (including geographic, sex, ethnic, and transmission variations), and the impacts of recent advances in prevention on HIV infection rates globally. Evidence-based content will be provided regarding 1) Safe prescribing of oral and injectable FDA-approved pharmacologic agents used for pre-exposure prophylaxis (PrEP); 2) Appropriate long- and short-term PrEP treatment plans, including the 2-1-1 method for PrEP; 3) Proper implementation of CDC algorithms for preventing HIV through post-exposure prophylaxis using pharmacologic methods; 4) Clinical interpretation of CD4 counts and HIV RNA levels (viral load) and the significance of getting patients to an undetectable viral load to eliminate their risk of sexual transmission; and 5) The responsibility of nurse practitioners in leading future scholarship and clinical practice initiatives aimed at preventing HIV infection and reducing health disparities in vulnerable populations.

 

An estimated 20% of adults will have some form of venous disease in their lives, making this a common complaint for many PCPs. Varicose veins can lead to irreversible complications if not identified and treated appropriately, including lymphedema, VTEs, and venous ulcers. Learn how to properly identify these patients and how to best manage their care. Learn about deep and superficial venous anatomy, ordering and interpreting duplex ultrasound reports, and surgical and non-surgical management of this common disease. We will cover best practice guidelines for the pharmacological and non-pharmacological management of VTEs in the outpatient setting. This presentation's goal is to highlight the importance of early identification of venous disease, and prescribing the appropriate treatment, in order to minimize complications from this common problem.